18 results
Profiles of Antidiabetic Medications - AACE 2018 

#Antidiabetic #Medications #Profiles #SideEffects #Table #DecisionAid #Orals #DM2 #Diabetes
of Antidiabetic Medications ... - AACE 2018 ... #Antidiabetic #Medications ... #SideEffects #Table
AACE/ACE 2018 Glycemic Control Algorithm

#AACE #2018 #Glycemic #Diabetes #DM2 #Control #Medication #Algorithm #Endocrinology #PrimaryCare #Management
AACE/ACE 2018 Glycemic ... Control Algorithm ... #AACE #2018 # ... #DM2 #Control #Medication ... #Algorithm #Endocrinology
Diabetes Medications Summary Table
Insulin
Lifestyle modifications
Metformin
Sulfonylureas
GLP-1 receptor agonists - ↓ major adverse CV events
TZDs
DPP-4 inhibitors
SGLT2 inhibitors -
Diabetes Medications ... Summary Table ... Insulin Lifestyle modifications ... #diabetes #medications ... #table #comparison
Table of Weight-Loss Medications approved by the FDA for the long-term treatment of Obesity

Mechanism of Action,
Table of Weight-Loss ... Medications approved ... mg #Obesity #Medications ... WeightLoss #AACE #2016 ... #Pharmacology #Table
Managing warfarin INR

Warfarin dosage must be individualized according to the patient's response to the drug, and
For most indications ... #management #algorithm ... pharmacology #treatment #medications ... #table #pharmacotherapy
Type 2 Diabetes - Screening, Diagnosis and Management Algorithm
Lifestyle  Modifications (Diet and Exercise) -> Start
and Management Algorithm ... Lifestyle Modifications ... Rubella) • Medications ... Targets #Management #algorithm
ISCHEMIA Trial - Management Algorithm for patients with Stable Angina

Stress Test -> ? +moderate or severe
Trial - Management Algorithm ... patients with Stable ... ISCHEMIA trial 2019 ... #ISCHEMIA #Stable ... Diagnosis #Management #Algorithm
What interventions do have proven mortality benefit?
The above factors predict that it's nearly impossible to prove
, Ridgeon 2016, ... and Landoni 2015 ... below is a list of medications ... #CriticalCare #Medications ... MortalityBenefit #Table
Daliresp (Roflumilast) 
Indication: Reduce risk of COPD exacerbations 
Drug Class: Selective Phosphodiesterase-4 (PDE4) Inhibitor 
GOLD 2019
Inhibitor GOLD 2019 ... Dosing: 250 mcg tablet ... daily The 2019 ... exacerbations. 2019 ... the use of this medication
AACE/ACE 2016 Postmenopausal Osteoporosis Treatment Algorithm

Evaluate for causes of secondary osteoporosis

Correct calcium/vitamin D deficiency and address
AACE/ACE 2016 Postmenopausal ... Osteoporosis Treatment Algorithm ... benefits and risks of medications ... Osteoporosis #AACE #2016 ... Postmenopausal #Treatment #Algorithm